Bacterial antigen mimicry drives MS
T cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Sitryx Therapeutics bags $30m in Series A Financing
/in News/by Thomas GabrielczykOxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and […]
Orchard plans to raise US$172m in ADS
/in News/by Thomas GabrielczykBritish gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, […]
Sphingotec raises 20m in growth equity financing
/in News/by Thomas GabrielczykDiagnostics company sphingotec GmbH successfully closed a 20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.
Sanofi and Evotec launch drug discovery PPP
/in News/by Thomas GabrielczykEvotec and Sanofi have launched a Public Private Partnership (PPP) aimed at partnering with academic groups in early stage drug discovery across multiple therapeutic areas.
Roche providing improved anti-Her2 bispecific antibody
/in News/by Thomas GabrielczykResearchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
Forbion closes Life Sciences VC Fund at 360m
/in News/by Thomas GabrielczykLife Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at 360m, 90m above its original target of 250m.
BIOSPAIN expanding
/in News/by Thomas GabrielczykMatured, diversified and willing to expand this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in […]
Minoryx bags 21.3m Series B financing
/in News/by Thomas GabrielczykBarcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another 21.3m in a Series B financing bringing its assets to a total of 50M.
PD-1+ T cells trigger pulmonary fibrosis
/in News/by Thomas GabrielczykA team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.